2012-09-30 16:17:30 -
New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
An analysis of upcoming catalysts that will affect selected companies in the Emerging Pharma peer set and Datamonitor's prediction of the outcome of these binary events. These catalysts include both PDUFA dates and expected Phase III trial results for key pipeline drugs.
Scope
* Focuses on the background and factors affecting the outcome of selected FDA drug approval decisions and Phase III trial results for covered companies
* Includes coverage of Amylin, ArQule, BioMarin, Elan, Exelixis, Ironwood, Medivation, NPS, Onyx, Regeneron, Rigel, Salix, Santarus, United Therapeutics
Full Report Details at
- www.fastmr.com/prod/464847_emerging_pharma_catalysts_h2_2012.asp ..
Highlights
Many important regulatory and clinical catalysts will occur in the second half of 2012 that will have a sizable impact both directly on the companies in
Datamonitor's Emerging Pharma peer set and also indirectly on the wider market.
Reasons to Get this Report
* Identify important catalysts that will have a large impact on the prospects for these Emerging Pharma companies and their products
* Assess the background and clinical data surrounding each of the listed products
* Analyze the factors affecting each catalyst and obtain Datamonitor's opinion on the outcome
Report Table of Contents:
ABOUT THIS REPORT
* PharmaVitae Explorer database
EXECUTIVE SUMMARY
* Catalysts
PDUFA DATES
* Regeneron
* Zaltrap: PDUFA - August 4
* Eylea: PDUFA - September 21
* Salix
* Crofelemer: PDUFA - September 5
* Ironwood
* Linaclotide: PDUFA - September 8
* Linaclotide clinical trials
* NPS Pharmaceuticals
* Gattex PDUFA - September 28
* Gattex should win approval based on positive Phase III data and CHMP positive opinion
* Amylin
* Metreleptin: PDUFA - October 3
* Ultra-rare nature of lipodystrophy lowers bar for approval
* Santarus
* Uceris: PDUFA - October 16
* Uceris clinical trials
* United Therapeutics
* Oral treprostinil: PDUFA - October 26
* Medivation
* Enzalutamide: PDUFA - November 21
* Onyx
* Regorafenib: PDUFA - November 23
* Positive data make approval likely, but uptake may be low
* Exelixis
* Cabozantinib: PDUFA - November 29
* Cabozantinib looks likely to be approved based on strong Phase III data
PHASE III TRIAL RESULTS
* ArQule: tivantinib - non-small cell lung cancer
* Tivantinib: Phase III results - H2 2012
* Interim analysis of MARQUEE trial expected in H2 2012
* BioMarin: Firdapse - Lambert-Eaton myasthenic syndrome
* Firdapse Phase III results - H2 2012
* Phase III LMS-002 trial
* BioMarin: GALNS - mucopolysaccharidosis IVA
* GALNS Phase III results - H2 2012
* Phase II trials
* Phase III trial
* Elan: bapineuzumab - Alzheimer's disease
* Bapineuzumab Phase III results - H2 2012
* Phase II trials
* Phase III trials
* Rigel: fostamatinib - rheumatoid arthritis
* Fostamatinib Phase III results - H2 2012
* Phase III program: OSKIRA and head-to-head clinical trials
APPENDIX
* References
* Datamonitor Reports
* Exchange rates
TABLES
* Table: Emerging Pharma catalysts, H2 2012
* Table: Recently launched Emerging Pharma products
* Table: Regeneron catalysts, H2 2012
* Table: Zaltrap colorectal cancer clinical trials
* Table: Summary of results from the Phase III VELOUR trial
* Table: Overview of pivotal Phase III data for Eylea and Lucentis in macular edema secondary to CRVO
* Table: Salix catalysts, H2 2012
* Table: Salix Phase III trials in diarrhea indication
* Table: Ironwood catalysts, H2 2012
* Table: Ironwood Pharmaceuticals' Phase III clinical trial program, including four pivotal trials and two safety studies
* Table: NPS Pharmaceuticals catalysts, H2 2012
* Table: NPS Phase III trials for small bowel syndrome
* Table: Amylin catalysts, H2 2012
* Table: Santarus catalysts, H2 2012
* Table: Overview of pivotal Phase III data for Uceris in ulcerative colitis
* Table: United Therapeutics catalysts, H2 2012
* Table: Medivation catalysts, H2 2012
* Table: Pivotal Phase III PREVAIL and AFFIRM trials for enzalutamide in prostate cancer
* Table: Onyx catalysts, H2 2012
* Table: Summary of efficacy results from the Phase III CORRECT trial
* Table: Exelixis catalysts, H2 2012
* Table: Phase II results for GALNS in MPS IVA
* Table: Phase II trial summary for bapineuzumab in Alzheimer's disease
* Table: Phase III trial summary for bapineuzumab in Alzheimer's disease
* Table: Summary of ongoing Phase III trials for FosD in rheumatoid arthritis
* Table: Exchange rates, 2012
FIGURES
* Figure: PharmaVitae Explorer
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at
www.fastmr.com/catalog/publishers.aspx?pubid=1002
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at
www.fastmr.com or call us at 1.800.844.8156.
